Trial Information

Summary: Prostate Cancer Study CLBH589C2208

Novartis Oncology is conducting this clinical trial is to find out the effects, both good and bad, of a study drug called panobinostat (LBH589) when given to people that have hormone refractory prostate cancer (HRPC) that is no longer responding to treatments that have already been given. The study drug Panobinostat (LBH589) is a medicine which has not been approved by FDA or other Health Authorities for the treatment of any medical conditions. Panobinostat (LBH589) is being tested in this study but is currently not "on the market" (available for you to buy) in any country.

Participants will be asked to visit the doctor's office or clinic from 1 to 2 times every week for the first three weeks for treatment and evaluations. They will be asked to visit the doctor's office once a week on treatment days starting in the fourth week of the study unless they experience any side effects from the study medications. Each visit should take about 1-3 hours; however, on day 1 of the first cycle, participants will be in the office for 9 to 10 hours.
For more information about this clinical trial, visit www.NovartisClinicalTrials.com

This site is run by CenterWatch, a publishing company that focuses on the clinical trials industry. The information provided in this service is designed to help patients find clinical trials that may be of interest to them, and to help patients contact the centers conducting the research. CenterWatch is neither promoting this research nor involved in conducting any of these trials.

Trial listings updated: June 27, 2008 at 1:00:35 PM